VG081821AC tablets for early to mid-stage Parkinson's disease
Part of Brain & nervous system clinical trials.
This trial tests a new oral medication, VG081821AC, in people with early to mid-stage Parkinson's disease. The goal is to see if it can improve movement symptoms and slow the progression of the condition, and it may offer a new treatment option for those not yet on levodopa.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with Parkinson's disease within the last 7 years.
- Your Parkinson's is at an early to mid stage (Hoehn-Yahr stage 1-3).
- You have not taken levodopa-containing medications in the past 4 weeks, or you can stop them for 4 weeks before the trial.
- You have not taken other Parkinson's medications (like dopamine agonists or MAO inhibitors) in the past 4 weeks, or can stop them for the required period.
- You are generally healthy, without severe heart, liver, kidney, or psychiatric conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called NouvNeu001 for people with Parkinson's disease. It aims to see if it's safe, feasible, and effective in improving motor symptoms.
This trial tests a new drug, PDR-001, to see if it can safely remove harmful proteins from the brain in people with early Parkinson's disease. It may help slow down the disease.
This study tests a new investigational vaccine called TRB-001 for people with early Parkinson's disease. It looks at whether the vaccine is safe and whether it can help the immune system fight the disease.
This trial tests a new treatment called XS411 for people with early-onset Parkinson's disease (age 50 or younger at diagnosis). It is for those whose motor symptoms are not well controlled with standard medications and who may benefit from a neurosurgical procedure.
This study tests whether an experimental oral medication (TJ0113) can improve symptoms in people diagnosed with Parkinson's disease before age 50. Participants must already be taking levodopa and keep their current Parkinson's medications unchanged during the study.
This early-stage trial tests a new medication called Lu AF28996 in Chinese patients with Parkinson's disease who experience predictable on-off episodes (times when medication works well versus poorly). The study aims to see if this drug can help reduce those difficult off periods.
Hear when a new Parkinson Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.